SPERO IDEABONANZA boys re vamped
purely technical and logical
biography how i made millions betting on peoples failiure
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.2675 USD
−68.57 M USD
27.40 M USD
37.55 M
About Spero Therapeutics, Inc.
Sector
Industry
CEO
Esther Rajavelu
Website
Headquarters
Cambridge
Founded
2013
FIGI
BBG00HXSJ1R2
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
SPRO - A perfect example of fundamental investment Fundamental Investment Example:
A company like SPRO with Price / Book<1, Price/Sale<1, LT debt/ Equity <0.1 and so on . I must say that this can be a perfect investment opportunity for a fundamental investor….. I hope this helps you to learn.
This is for an educational purpose only.
SPRO Final 3rd Testing SuccessfulI bought this stock too early and watch it get clobbered. Then they announced their drug final 3rd stage testing was successful. This company is a $30 stock but they still have to raise money and go to market. BUT this guarantees they will be successful.
Flag Decision Shortly SPROThis pattern build over many months when broken up or down will signal the future direction. I am buying with stop at 11.60 looking for upside break out in the next month.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of SPRO is 0.7400 USD — it has decreased by −3.87% in the past 24 hours. Watch Spero Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Spero Therapeutics, Inc. stocks are traded under the ticker SPRO.
SPRO stock has risen by 18.04% compared to the previous week, the month change is a −4.61% fall, over the last year Spero Therapeutics, Inc. has showed a −47.14% decrease.
We've gathered analysts' opinions on Spero Therapeutics, Inc. future price: according to them, SPRO price has a max estimate of 5.00 USD and a min estimate of 5.00 USD. Watch SPRO chart and read a more detailed Spero Therapeutics, Inc. stock forecast: see what analysts think of Spero Therapeutics, Inc. and suggest that you do with its stocks.
SPRO reached its all-time high on Dec 28, 2020 with the price of 23.6390 USD, and its all-time low was 0.5052 USD and was reached on Apr 9, 2025. View more price dynamics on SPRO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SPRO stock is 7.81% volatile and has beta coefficient of 1.37. Track Spero Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Spero Therapeutics, Inc. there?
Today Spero Therapeutics, Inc. has the market capitalization of 40.53 M, it has increased by 26.19% over the last week.
Yes, you can track Spero Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Spero Therapeutics, Inc. is going to release the next earnings report on May 9, 2025. Keep track of upcoming events with our Earnings Calendar.
SPRO earnings for the last quarter are −0.38 USD per share, whereas the estimation was −0.31 USD resulting in a −22.58% surprise. The estimated earnings for the next quarter are −0.44 USD per share. See more details about Spero Therapeutics, Inc. earnings.
Spero Therapeutics, Inc. revenue for the last quarter amounts to 15.04 M USD, despite the estimated figure of 12.40 M USD. In the next quarter, revenue is expected to reach 11.00 M USD.
SPRO net income for the last quarter is −20.89 M USD, while the quarter before that showed −17.15 M USD of net income which accounts for −21.82% change. Track more Spero Therapeutics, Inc. financial stats to get the full picture.
No, SPRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 22, 2025, the company has 32 employees. See our rating of the largest employees — is Spero Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Spero Therapeutics, Inc. EBITDA is −93.06 M USD, and current EBITDA margin is −339.70%. See more stats in Spero Therapeutics, Inc. financial statements.
Like other stocks, SPRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Spero Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Spero Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Spero Therapeutics, Inc. stock shows the sell signal. See more of Spero Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.